Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated:  9/22/2016
GSK Investigational Site
mi
from
New York, NY
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated: 9/22/2016
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated:  9/22/2016
GSK Investigational Site
mi
from
Toledo, OH
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated: 9/22/2016
GSK Investigational Site
mi
from
Toledo, OH
Click here to add this to my saved trials
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated:  9/22/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated: 9/22/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated:  9/22/2016
GSK Investigational Site
mi
from
Nashville, TN
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated: 9/22/2016
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated:  9/22/2016
GSK Investigational Site
mi
from
Dallas, TX
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated: 9/22/2016
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated:  9/22/2016
GSK Investigational Site
mi
from
Richmond, VA
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Status: Enrolling
Updated: 9/22/2016
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy
A Randomized, Double-blind, Placebo-Controlled, Cross-over Study on the Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy
Status: Enrolling
Updated:  10/6/2016
Eastern Virgnia Medical School, Strelitz Diabetes Center
mi
from
Norfolk, VA
The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy
A Randomized, Double-blind, Placebo-Controlled, Cross-over Study on the Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy
Status: Enrolling
Updated: 10/6/2016
Eastern Virgnia Medical School, Strelitz Diabetes Center
mi
from
Norfolk, VA
Click here to add this to my saved trials
The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy
A Randomized, Double-blind, Placebo-Controlled, Cross-over Study on the Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy
Status: Enrolling
Updated:  10/6/2016
Strelitz Diabetes Center
mi
from
Norfolk, VA
The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy
A Randomized, Double-blind, Placebo-Controlled, Cross-over Study on the Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy
Status: Enrolling
Updated: 10/6/2016
Strelitz Diabetes Center
mi
from
Norfolk, VA
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
For Drug Shipment only - The University of Alabama at Birmingham
mi
from
Birmingham, AL
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
For Drug Shipment only - The University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
The Kirklin Clinic of UAB Hospital
mi
from
Birmingham, AL
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
The Kirklin Clinic of UAB Hospital
mi
from
Birmingham, AL
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Mayo Clinic
mi
from
Phoenix, AZ
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
University of California, Irvine (Drug Shipment)
mi
from
Irvine, CA
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
University of California, Irvine (Drug Shipment)
mi
from
Irvine, CA
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
University of California, Irvine
mi
from
Irvine, CA
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Ronald Regan UCLA Medical Center Drug Information Center - DRUG SHIPMENT ONLY
mi
from
Los Angeles, CA
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Ronald Regan UCLA Medical Center Drug Information Center - DRUG SHIPMENT ONLY
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
UCLA Neurology Clinic
mi
from
Los Angeles, CA
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
UCLA Neurology Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Rocky Mountain Movement Disorders Center
mi
from
Englewood, CO
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Rocky Mountain Movement Disorders Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
University of Florida Center for Movement Disorders and Neurorestoration
mi
from
Gainesville, FL
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
University of Florida Center for Movement Disorders and Neurorestoration
mi
from
Gainesville, FL
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Indiana University Health Neuroscience Center
mi
from
Indianapolis, IN
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Indiana University Health Neuroscience Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Massachusetts General Hospital
mi
from
Charlestown, MA
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Massachusetts General Hospital
mi
from
Charlestown, MA
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Albany Medical College
mi
from
Albany, NY
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Albany Medical College
mi
from
Albany, NY
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Wake Forest Baptist Medical Center - Dept. of Neurology
mi
from
Winston-Salem, NC
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Wake Forest Baptist Medical Center - Dept. of Neurology
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Drug Shipment Address - Cleveland Clinic Foundation
mi
from
Cleveland, OH
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Drug Shipment Address - Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Davis Medical Center
mi
from
Columbus, OH
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Davis Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Wexner Medical Center at the Ohio State University
mi
from
Columbus, OH
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Wexner Medical Center at the Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
Baylor College of Medicine
mi
from
Houston, TX
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated:  10/12/2016
The University of British Columbia, Centre for Huntington Disease
mi
from
Vancouver,
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status: Enrolling
Updated: 10/12/2016
The University of British Columbia, Centre for Huntington Disease
mi
from
Vancouver,
Click here to add this to my saved trials
Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients
Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients
Status: Enrolling
Updated:  10/13/2016
New York University School of Medicine
mi
from
New York, NY
Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients
Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients
Status: Enrolling
Updated: 10/13/2016
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Birmingham, AL
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Mesa, AZ
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Phoenix, AZ
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Sun City, AZ
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Sun City, AZ
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Anaheim, CA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Burlingame, CA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Burlingame, CA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Long Beach, CA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Newport Beach, CA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Pasadena, CA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Redondo Beach, CA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Redondo Beach, CA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Santa Monica, CA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Stanford, CA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Stanford, CA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Winnetka, CA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Winnetka, CA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Boca Raton, FL
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Boca Raton, FL
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Coeur d'Alene, ID
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Springfield, MA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Springfield, MA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
West Yarmouth, MA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
West Yarmouth, MA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Worcester, MA
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Worcester, MA
Click here to add this to my saved trials
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated:  10/17/2016
GSK Investigational Site
mi
from
Kalamazoo, MI
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Status: Enrolling
Updated: 10/17/2016
GSK Investigational Site
mi
from
Kalamazoo, MI
Click here to add this to my saved trials